News » marketed by AstraZeneca

Arimidex [Anastrozole] marketed by AstraZeneca Pharmaceuticals LP is a drug indicated in the treatment of adjuvant treatment [treatment following surgery with or without radiation] of postmenopausal women with hormone receptor-positive early breast cancer. It decreases the amount of estrogen in the body. It is chemically described as 1 Teemu Pulkkinen Golden Knights Jersey , 3-Benzenediacetonitrile, a, a, a', a'- Tetramethyl-5-(1H-1, 2, 4-triazol-1-ylmethyl). Estrogen receptor positive breast cancer: The estrogen receptor (ER) is a member of the nuclear hormone family of intracellular receptors which is activated by the hormone 17脦虏-estradiol (estrogen). The main function of the estrogen receptor is to act as a DNA binding transcription factor which would regulate gene expression. Apart from this function, the estrogen receptor also has additional functions independent of DNA binding. There are two types of estrogen receptors, 脦卤 and 脦虏, both encoded by different genome [ESR1 on the sixth chromosome and ESR2 on the fourteenth chromosome respectively] In 70% cases of breast cancer, over expression of the estrogen receptor has been found, termed as ER positive. Researches postulate two theses for the occurrence of the same: - Binding of estrogen to the ER stimulates proliferation of mammary cells, this result in increase in cell division and DNA replication leading to mutations. - It is thought that estrogen metabolism could lead to production of genotoxic wastes. Both these processes could result in the disruption of cell cycle, apoptosis and DNA repair and therefore tumor formation. ER脦卤 is certainly associated with more differentiated tumors, while evidence that ER脦虏 is involved is controversial. Different versions of the ESR1 gene have been identified (with single-nucleotide polymorphisms) and are associated with different risks of developing breast cancer. Particularly in postmenopausal women, the principal source of circulating estrogen (primarily Estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues, with further conversion of estrone to estradiol. Many breast cancers also contain aromatase; the importance of tumor-generated estrogens is uncertain. Arimidex [Anastrozole] is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to Arimidex [Anastrozole] Anastrozole belongs to the class of aromatase inhibitors, where it inhibits the enzyme aromatase which is responsible for the conversion of androgens to estrogen, meaning it selectively lowers the serum estradiol levels and at the same time doesn芒鈧劉t have any effect on the formation of adrenal corticosteroids or aldosterone. Basically it is a selective non steroidal aromatase inhibitor. Orally administered Arimidex [anastrozole] is well absorbed into the systemic circulation. Its absorption is not affected by food. With a half life of around 50 hours in post-menopausal females, it is excreted mainly via hepatic metabolism and by a lesser extent by renal metabolism